Purple Biotech Q2 EPS $(0.25) Beats $(0.26) Estimate
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech (NASDAQ:PPBT) reported Q2 losses of $(0.25) per share, beating the analyst consensus estimate of $(0.26) by 3.85 percent. This represents a 225 percent decrease over earnings of $0.20 per share from the same period last year.
August 22, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Purple Biotech's Q2 earnings beat estimates but showed a significant decrease from last year. This mixed result could lead to uncertain market reactions.
Purple Biotech's earnings beat estimates, which is generally positive for the stock. However, the significant decrease from last year's earnings could be a concern for investors, leading to potential uncertainty in the stock's short-term performance.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100